Suzanne Craft
Wake Forest Alzheimer's Disease Research Center · Wake Forest University Health Sciences / Wake Forest School of Medicine · Wake Forest University Health Sciences
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Suzanne Craft as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:13 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07756294 · Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's DiseaseWake Forest University Health Sciences · not yet recruiting · Alzheimer Disease · principal investigator
- Ph2NCT05081219 · SNIFF - Combo INI+EMPA TrialWake Forest University Health Sciences · completed · Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease · principal investigator
- Ph2NCT05006599 · SNIFF - 3-Week Aptar CPS DeviceWake Forest University Health Sciences · withdrawn · Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease, Early Onset · principal investigator
- Ph2NCT04199767 · SNIFF Multi-Device Study 2Wake Forest University Health Sciences · completed · Mild Cognitive Impairment, Cognitive Impairment · principal investigator
- Ph2NCT03857321 · Study of Nasal Insulin to Fight Forgetfulness - Device StudyWake Forest University Health Sciences · completed · Mild Cognitive Impairment, Cognitive Impairment · principal investigator
- N/ANCT03472664 · Brain Energy for Amyloid Transformation in Alzheimer's Disease StudyWake Forest University Health Sciences · completed · Alzheimer Disease, Mild Cognitive Impairment · principal investigator
- N/ANCT03130036 · Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's DiseaseWake Forest University Health Sciences · completed · Mild Cognitive Impairment · principal investigator
- N/ANCT03089827 · Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's DiseaseWake Forest University Health Sciences · enrolling by invitation · Alzheimer Disease, Mild Cognitive Impairment · principal investigator
- N/ANCT02984540 · Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's DiseaseWake Forest University Health Sciences · completed · Mild Cognitive Impairment, Insulin Resistance · principal investigator
- N/ANCT02463084 · Macronutrient Effects on Alzheimer's Disease (MEAL-2)Wake Forest University Health Sciences · completed · Prediabetic State, Insulin Resistance, Middle Age · principal investigator
- Ph1NCT02462161 · Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin AspartWake Forest University Health Sciences · completed · Alzheimer's Disease, Mild Cognitive Impairment · principal investigator
- Ph2/Ph3NCT01767909 · The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)University of Southern California · completed · Amnestic Mild Cognitive Impairment, Alzheimer's Disease · study director
- Ph2NCT01595646 · Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)Wake Forest University Health Sciences · completed · Alzheimer's Disease, Mild Cognitive Impairment · principal investigator
- Ph2NCT01547169 · Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 DaysUniversity of Washington · completed · Alzheimer's Disease, Mild Cognitive Impairment · principal investigator
- Ph2NCT00438568 · SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)University of Washington · completed · Mild Cognitive Impairment, Alzheimer's Disease · principal investigator
- Ph2NCT00242593 · Rosiglitazone Effects on Cognition for Adults in Later LifeUniversity of Washington · unknown · Mild Cognitive Impairment · principal investigator
- Ph4NCT00212290 · Insulin Resistance and Central Nervous System (CNS) Function in Type 2 DiabetesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · completed · Insulin Resistance, Type 2 Diabetes Mellitus · principal investigator
- Ph2NCT00018343 · Alzheimer's Disease and Aging: Therapeutic Potential of EstrogenUS Department of Veterans Affairs · completed · Alzheimer's Disease · unknown
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Liquid biopsies to evaluate the effect of a ketogenic diet on molecular circuitries associated with mild cognitive impairmentR01AG084696 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2024 to 2026 · $760,997 awarded in 2026Same name and institution; not confirmed by an ID
- Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2021 to 2026 · $4,510,117 awarded in 2026Same name and institution; not confirmed by an ID
- Development of an Innovative Vervet (Chlorocebus aethiops sabaeus) Model of Early Alzheimer's-like Neuropathology and SymptomatologyR24AG073199 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2021 to 2024 · $1,290,401 awarded in 2024Same name and institution; not confirmed by an ID
- PET imaging of microtubules in cognitively normal and impaired older adultsR56AG081860 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2023 · $926,389 awarded in 2023Same name and institution; not confirmed by an ID
- Modified Ketogenic Diet Effects on Alzheimer's Disease Biomarkers and Cognition in Mild Cognitive ImpairmentR01AG055122 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2017 to 2022 · $1,014,666 awarded in 2022Grant number is on one of their registry trials
- Wake Forest Alzheimer's Disease Core CenterP30AG049638 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2016 to 2020 · $2,878,019 awarded in 2020Same name and institution; not confirmed by an ID
- Effects of Western and Mediterranean Diets on Metabolic and Neuropathologic Risk Factors for Alzheimer's Disease in Nonhuman PrimatesRF1AG058829 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2018 · $2,771,584 awarded in 2018Same name and institution; not confirmed by an ID
- Therapeutic Effect of Intranasal Insulin on Cognition, Function, and AD BiomarkerRF1AG041845 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2012 to 2017 · $3,435,574 awarded in 2017Grant number is on one of their registry trials
- Beta-cell Function and Cognition in the Restoring Insulin Secretion (RISE) StudyR01DK099164 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2013 to 2016 · $519,974 awarded in 2016Same name and institution; not confirmed by an ID
- Glucose Regulation and Memory in Alzheimer's DiseaseR37AG010880 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2005 to 2014 · $588,237 awarded in 2014Same name and institution; not confirmed by an ID
- THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · fiscal years 2000 to 2014 · $190,026 awarded in 2014Grant number is on one of their registry trials
- Neurobehavior, Neuroendocrinology, and Genetics of ADT32AG000258 · NIA · UNIVERSITY OF WASHINGTON · fiscal years 2004 to 2011 · $433,274 awarded in 2011Same name and institution; not confirmed by an ID
- The Effects of Rosiglitazone in Patients with MCIR01AG025502 · NIA · SEATTLE INST FOR BIOMEDICAL/CLINICAL RES · fiscal years 2005 to 2009 · $99,694 awarded in 2009Grant number is on one of their registry trials
- Therapeutic Effects of Intranasal Insulin in ADR01AG027415 · NIA · UNIVERSITY OF WASHINGTON · fiscal years 2006 to 2008 · $374,682 awarded in 2008Grant number is on one of their registry trials
- GLUCOSE REGULATION AND MEMORY IN ALZHEIMER'S DISEASER01AG010880 · NIA · UNIVERSITY OF WASHINGTON · fiscal years 1992 to 2004 · $199,195 awarded in 2004Same name and institution; not confirmed by an ID
- Insulin Resistance and CNS Function in Type 2 DiabetesR01DK061606 · NIDDK · UNIVERSITY OF WASHINGTON · fiscal years 2002 to 2004 · $50,299 awarded in 2004Same name and institution; not confirmed by an ID
- GLUCOSE REGULATION AND MEMORY IN ALZHEIMER'S DISEASEP01AG003991 · NIA · WASHINGTON UNIVERSITY · fiscal years 1996 to 1999 · $207,587 awarded in 1999Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:13 UTC. The ranking covers the 200 most relevant of 77 PubMed records, and a shared surname and initials can bring in a namesake. All 77 on PubMed
- Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.Arch Neurol · 20121,030 citationsRCR 34.3
- 883 citationsRCR 28.4
- 665 citationsRCR 17.6
- A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease.Neurology · 2015587 citationsRCR 23.4
- Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.Pharmacogenomics J · 2006562 citationsRCR 14.0
- Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype.Neurobiol Aging · 2006532 citationsRCR 13.8
- Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.Am J Geriatr Psychiatry · 2005522 citationsRCR 12.6
- Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes.Arch Neurol · 2011522 citationsRCR 15.7
- Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.Neuropsychopharmacology · 1999460 citationsRCR 12.9
- 420 citationsRCR 16.1